



Supplementary material

Supplementary Figure 1: The FluidCrystal® drug delivery system¹⁻⁵



In ACROINNOVA 1, CAM2029 was administered via pre-filled syringes.⁵ Only the pre-filled pen autoinjector is available following marketing authorization.⁶

Supplementary Figure 2: Overview of AIS, AcroQoL and TSQM



ACROINNOVA 1 and ACROINNOVA 2 were not powered to assess changes in acromegaly symptom severity using the AIS, AcroQoL or TSQM.

*In ACROINNOVA 1 and 2, paresthesia was included in addition to the five symptoms assessed with the AIS in Fleseriu *et al* 2020;⁵ †A 1–5 Likert scale measuring the frequency of occurrence (always, most of the time, sometimes, rarely, or never) or the degree of agreement with the items (completely agree, moderately agree, neither agree nor disagree, moderately disagree, or completely disagree); ‡The psychological domain is subdivided into physical appearance and impact of the disease on personal relationships.

Supplementary Table 1: Patient demographics and medical histories at screening

	Directly continued (N=20)	Restarted (N=23)	Overall (N=43)
Mean age, years (SD)	60.5 (10.9)	51.3 (14.0)	55.6 (13.3)
Sex, n (%)			
Female	14 (70.0)	13 (56.5)	27 (62.8)
Male	6 (30.0)	10 (43.5)	16 (37.2)
Mean time since diagnosis, years (SD)	14.4 (9.3)	9.7 (8.2)	11.8 (9.0)
Prior pituitary surgery, n (%)	18 (90.0)	20 (87.0)	38 (88.4)
Past medications,* n (%)	20 (100)	23 (100)	43 (100)
Octreotide	15 (75.0)	15 (65.2)	30 (69.8)
Lanreotide	9 (45.0)	13 (56.5)	22 (51.2)
Cabergoline	1 (5.0)	6 (26.1)	7 (16.3)
Bromocriptine	1 (5.0)	1 (4.3)	2 (4.7)
Pegvisomant	1 (5.0)	1 (4.3)	2 (4.7)
IGF-I ≤ULN,† n/N (%)	12/19 (63.2)	11/23 (47.8)	23/42 (54.8)

Demographic data from the screening assessments at the start of ACROINNOVA 1 and ACROINNOVA 2. Extension safety analysis set (all patients in the directly continued group and all patients in the restarted group who received at least one dose of CAM2029 during the extension).

*Any time prior to enrollment in ACROINNOVA 1 (prior-CAM2029 and prior-placebo) or the core phase of ACROINNOVA 2 (directly enrolled);

†At SoC baseline; extension efficacy analysis set (all patients who received at least one dose of CAM2029 and completed at least one efficacy assessment during the extension). IGF-I, insulin-like growth factor I; SD, standard deviation; SoC, standard of care; ULN, upper limit of normal per age and sex.

Supplementary Table 2: AEs by preferred term reported in the extension phase of ACROINNOVA 2

AE by preferred term reported in ≥3 patients overall, n (%)	Directly continued (N=20)	Restarted (N=23)	Overall (N=43)
Headache	3 (15.0)	5 (21.7)	8 (18.6)
Arthralgia	2 (10.0)	5 (21.7)	7 (16.3)
Injection site mass	1 (5.0)	4 (17.4)	5 (11.6)
Injection site swelling	1 (5.0)	4 (17.4)	5 (11.6)
Injection site erythema	1 (5.0)	3 (13.0)	4 (9.3)
Injection site nodule	0	3 (13.0)	3 (7.0)
Soft tissue swelling	0	3 (13.0)	3 (7.0)
Injection site pain	2 (10.0)	1 (4.3)	3 (7.0)
COVID-19	1 (5.0)	2 (8.7)	3 (7.0)
Upper respiratory tract infection	1 (5.0)	2 (8.7)	3 (7.0)
Diarrhea	1 (5.0)	2 (8.7)	3 (7.0)

Extension safety analysis set. Table shows TEAEs. AE, adverse event; COVID-19, Coronavirus disease 2019; TEAE, treatment-emergent adverse event.

References

1. Tiberg F *et al.* *Chem Lett* 2012;41:1090–2.
2. Tiberg F, Johnsson M. *J Drug Deliv Sci Technol* 2011;21:101–9.
3. Engstedt J *et al.* *Colloids Surf B Biointerfaces* 2024;239:113955.
4. Tiberg F *et al.* *Br J Clin Pharmacol* 2015;80:460–72.
5. Ferone D *et al.* *J Clin Endocrinol Metab* 2025;110:1729–39.
6. Camurus AB. Ocyyesa® (octreotide). UK summary of product characteristics, 2025.
7. Fleseriu M *et al.* *Pituitary* 2020;23:347–58.
8. Fleseriu M *et al.* *Front Endocrinol* 2021;12:627711.
9. Badia X *et al.* *Health Qual Life Outcomes* 2004;2:13.
10. Atkinson MJ *et al.* *Health Qual Life Outcomes* 2004;2:12.